Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank - 19/06/20
Doi : 10.1016/j.ahj.2020.02.012
Jonathan H. Seltzer, MD, MBA, MA a, ⁎ 
, Ann Farrell, MD b , Neil Goldenberg, MD, PhD c , Christoph Hornik, MD, PhD, MPH d , Daniel Keene, MD e , Mitchell W. Krucoff, MD f , Concetta Lipardi, MD, PhD g , Patricia Massicotte, MD h , Dirk Mentzer, MD i , Paul Monagle, MBBS, MD, MSc, FRACP, FRCPA j , Courtney Thornburg, MD, MS k , James H. Revkin, MD l , Shetarra Walker, MD, MSCR m , Diptee Gajjar, BPharm, PhD n
, Ann Farrell, MD b , Neil Goldenberg, MD, PhD c , Christoph Hornik, MD, PhD, MPH d , Daniel Keene, MD e , Mitchell W. Krucoff, MD f , Concetta Lipardi, MD, PhD g , Patricia Massicotte, MD h , Dirk Mentzer, MD i , Paul Monagle, MBBS, MD, MSc, FRACP, FRCPA j , Courtney Thornburg, MD, MS k , James H. Revkin, MD l , Shetarra Walker, MD, MSCR m , Diptee Gajjar, BPharm, PhD n a WCG-ACI Clinical, 3 Bala Cynwyd, PA 19004
b Division of Hematology Products, Office of Drug Evaluation 1, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland
c Divisions of Hematology, Johns Hopkins School of Medicine, Baltimore, MD, Johns Hopkins Pediatric Thrombosis Program, St. Petersburg, FL, – Baltimore, MD, All Children’s Research Institute
d Duke University, Duke Clinical Research Institute
e Office of Clinical Trials/ Bureau des Essais Clinique, Centre for Regulatory Excellence, Statistics and Trials/Centre d’Excellence Réglementaire, de Statistiques et Essais Clinique, Ottawa, Ontario, Canada
f Duke University Medical Center
g Janssen Research and Development LLC, Rahway, NJ
h Department of Pediatrics, University of Alberta
i Paul-Ehrlich-Institut
j The University of Melbourne Academic Centre, Royal Children's Hospital, The University of Melbourne
k UC San Diego, Hemophilia and Thrombosis Treatment Center, Rady Children’s Hospital San Diego
l Global Clinical Lead, Apixaban, Pfizer Inc., Global Product Development, CVMET Therapeutic Area, Groton, CT
m Center for Drug Evaluation and Research, U.S. Food and Drug Administration
n Intercontinental Regulatory Strategy Lead, Bristol-Myers Squibb
⁎Reprint requests: Jonathan H. Seltzer, MD, MBA, MA, WCG-ACI Clinical, 3 Bala Cynwyd, PA 19004.WCG-ACI Clinical, 3 Bala CynwydPA19004
Plan
© 2020
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 224
P. 138-147 - juin 2020 Retour au numéro
Article précédent
- Clinical decision support for atrial fibrillation in primary care: Steps forward
- Michael J. Thibert, Nathaniel M. Hawkins, Jason G. Andrade
- COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial
- Georgios J. Vlachojannis, Rosanne F. Vogel, Jeroen M. Wilschut, Miguel E. Lemmert, Ronak Delewi, Roberto Diletti, Ria van Vliet, Nancy van der Waarden, Rutger-Jan Nuis, Valeria Paradies, Dimitrios Alexopoulos, Felix Zijlstra, Gilles Montalescot, Dominick J. Angiolillo, Mitchell W. Krucoff, Nicolas M. Van Mieghem, Pieter C. Smits
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?